ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1736

Multi-Model Evaluation of the Impact of CD14 on Synovial Inflammation and Pain During PTOA.

Kevin Burt1, Sanique South2, Natalie Adamczyk3, Shingo Ishihara3, Vu Nguyen4, Robert Mauck4, Anne-Marie Malfait5, Timothy Griffin6, Rachel Miller7 and Carla Scanzello1, 1University of Pennsylvania, Philadelphia, PA, 2University of Oregon, Eugene, 3Rush University, Chicago, 4University of Pennsylvania, Philadelphia, 5Rush University, Oak Park, IL, 6Oklahoma Medical Research Foundation, Oklahoma City, 7Rush University Medical Center, Chicago, IL

Meeting: ACR Convergence 2025

Keywords: Animal Model, Inflammation, Osteoarthritis, pain, Synovitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: Abstracts: Osteoarthritis & Joint Biology – Basic Science (1734–1739)

Session Type: Abstract Session

Session Time: 10:30AM-10:45AM

Background/Purpose: Soluble CD14, a co-receptor of inflammatory toll-like receptor signaling that is produced primarily by monocytes/macrophages, is present in synovial fluid in patients with OA and positively associates with joint space narrowing and pain. Utilizing both global genetic deletion of CD14 and intra-articular CD14 blockade across mild to severe models of murine PTOA, we aimed to test the hypothesis that CD14 inhibition can attenuate synovial inflammation and associated pain during disease progression.

Methods: DMM: Destabilization of the medial meniscus (DMM) surgery was performed in 12-wk old male C57BL/6 mice. 2) PMX: Partial meniscectomy (PMX) surgery was performed in 12-wk old male mice. 3) HFD-ACLR: Nonsurgical anterior cruciate ligament rupture (ACLR) was performed via overloading in 36-wk old female mice fed a high fat diet (HFD). CD14 knockout: A global genetic knockout of CD14 was utilized and evaluated in the DMM and PMX models. Drug intervention: WT mice were treated intra-articularly (IA) with either an anti-CD14 monoclonal antibody or an IgG2a control (0.5mg/kg). Mice received 3 weekly injections beginning 48 hours post DMM or ACLR injuries. Evoked pain: Knee hyperalgesia was measured using a pressure application measurement (PAM) device. Spontaneous pain behavioral: Spontaneous cage behavior was evaluated using the Laboratory Animal Behavior Observation Registration and Analysis SystemTM. Paw weight bearing distribution and rearing behavior was measured using the Advanced Dynamic Weight Bearing system or a static incapacitance meter system. Single-cell sequencing (scRNA-seq) (n=15): Synovial cells were isolated from DMM- and sham- operated knee joints 4-wks post-surgery. scRNA-seq data was processed using Seurat.

Results: Global deletion of CD14 mitigated knee hyperalgesia in both DMM and PMX models of PTOA, with a significant increase in withdrawal threshold in CD14-KO mice compared to WT post-injury (Fig. 1A-C). Further, delivery of a CD14 blocking antibody mitigated knee hyperalgesia in both DMM and HFD-ACLR models of PTOA (Fig. 1D-F). Spontaneous pain behavior analysis revealed that genetic deletion of CD14 increased mobility (rearing time) in the DMM model, comparing to WT. Further, a protection from weight bearing asymmetry was observed following PMX injury in CD14-KO mice compared to WT (Fig. 1A-C). IA delivery of anti-CD14 increased rearing activity following DMM and protected from weight bearing asymmetry following ACLR injury, both compared to the IgG control (Fig. 1D-F). Mild attenuation of OA histopathology was observed across models. Lastly, synovial scRNA-seq analysis at 4-wks post DMM revealed clear decreases across multiple monocyte populations, as well as a differential modulation of multiple fibroblast populations within the CD14-KO synovium compared to WT (Fig. 2).

Conclusion: The consistent attenuation of pain behavior in both mild and severe models of PTOA strongly supports the potential of targeting CD14 to treat painful OA. Our scRNA-seq results suggest that the protective effects may be mediated in part by decreased inflammatory signaling within the synovium, which influenced both the myeloid and fibroblast populations that emerge after injury.

Supporting image 1Figure 1: (A,D) Study schematic. (B,C,E,F) Knee hyperalgesia measured via withdrawal threshold (g). (B,E) Time spent rearing (sec). (C) Weight bearing asymmetry measured as (C) the difference between rear right (DMM) to rear left paw (unoperated) weight (g) or (F) as front to rear paw weight bearing ratio (%/%).

Supporting image 2Figure 2: (A) UMAP of cell clusters within WT and CD14 KO synovium harvested 4-wks post injury with re-clustered monocyte populations delineated. (B) Monocyte specific cell cluster breakdown represented as the number and percentage of total cells within monocyte clusters. (C) UMAP of re-clustered monocyte populations. (C) UMAP of cell clusters within WT and CD14 KO synovium harvested 4-wks post injury with fibroblast clusters (Clusters 1, 4, & 9) delineated. (D) Fibroblast cell cluster breakdown represented as the number and percentage of total cells within fibroblast clusters. (pooled n=15/group).


Disclosures: K. Burt: None; S. South: None; N. Adamczyk: None; S. Ishihara: None; V. Nguyen: None; R. Mauck: None; A. Malfait: Eli Lilly, 5, Merck, 2, Novartis, 2, Orion, 5, Roivant, 2; T. Griffin: COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS USING A CD14 INHIBITOR, 10, Novo Nordisk, 2; R. Miller: None; C. Scanzello: COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS USING A CD14 INHIBITOR, 10.

To cite this abstract in AMA style:

Burt K, South S, Adamczyk N, Ishihara S, Nguyen V, Mauck R, Malfait A, Griffin T, Miller R, Scanzello C. Multi-Model Evaluation of the Impact of CD14 on Synovial Inflammation and Pain During PTOA. [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/multi-model-evaluation-of-the-impact-of-cd14-on-synovial-inflammation-and-pain-during-ptoa/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multi-model-evaluation-of-the-impact-of-cd14-on-synovial-inflammation-and-pain-during-ptoa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology